Loading...
•
Dec 31, 2019
Ionis Q4 2019 Earnings Report
Ionis's revenue increased significantly, driven by SPINRAZA royalties and R&D revenue, which led to improved operating and net income.
Key Takeaways
Ionis Pharmaceuticals reported strong fourth-quarter and full-year 2019 financial results, with revenues nearly doubling due to SPINRAZA's performance and increased R&D revenue. The company achieved profitability, increased its cash position, and invested in its pipeline and technology.
Ionis's 2019 revenues nearly doubled, exceeding guidance.
SPINRAZA royalties increased by more than 20 percent.
Operating and net income significantly improved on a GAAP basis.
Ionis increased its cash position to $2.5 billion.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.com Forward Guidance
The Company’s full year 2020 financial guidance consists of the following components (on a non-GAAP basis):
Positive Outlook
- Revenue >$700 million
- Meaningfully Profitable
Challenges Ahead
- Operating Expenses ~$650 million to $690 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income